Edward Wirth
CIK 1532558 · Chief Medical Officer · last filed 2019-03-21
Edward Wirth is a Chief Medical Officer who has filed 17 SEC Form 4 insider transactions across 2 companies since 2015. Across all open-market trades the lifetime net is −$124.0K, making them a net seller over the disclosed history. 2 SEC filings were submitted jointly with Lineage Cell Therapeutics, Inc.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
AST.WS price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
ONE BROADWAY, 14TH FLOOR
CAMBRIDGE, MA 02142
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| Asterias Biotherapeutics, Inc. (AST) Delisted | Chief Medical Officer | 267,194 | — | — | -$17.3K | 8 | 2019-03-05 |
| Asterias Biotherapeutics, Inc. (AST.WS) Delisted | Chief Medical Officer | 85,177 | — | — | -$106.7K | 7 | 2017-06-07 |
Recent Filings
17 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2019-03-21 | — | Grant (A) | — | $0 | |
| 2019-03-05 | Asterias Biotherapeutics, Inc. (AST) Delisted | Mixed | +107,626 | -$46.4K | EDGAR |
| 2019-01-04 | Asterias Biotherapeutics, Inc. (AST) Delisted | Tax (F) | −20,440 | -$13.9K | EDGAR |
| 2018-03-30 | Asterias Biotherapeutics, Inc. (AST) Delisted | Tax (F) | −6,483 | -$9.4K | EDGAR |
| 2018-03-19 | Asterias Biotherapeutics, Inc. (AST) Delisted | Mixed | +101,314 | -$44.2K | EDGAR |
| 2017-06-07 | Asterias Biotherapeutics, Inc. (AST.WS) Delisted | Tax (F) | −6,745 | -$21.6K | EDGAR |
| 2017-04-03 | Asterias Biotherapeutics, Inc. (AST.WS) Delisted | Grant (A) | +91,922 | $0 | EDGAR |
| 2017-01-11 | Asterias Biotherapeutics, Inc. (AST.WS) Delisted | Mixed | −5,471 | -$15.7K | EDGAR |
| 2017-01-06 | Asterias Biotherapeutics, Inc. (AST.WS) Delisted | Mixed | — | -$6.7K | EDGAR |
| 2016-11-21 | Asterias Biotherapeutics, Inc. (AST.WS) Delisted | Mixed | — | -$6.7K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.